1. Home
  2. PLUR vs RDI Comparison

PLUR vs RDI Comparison

Compare PLUR & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$2.09

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

RDI

Reading International Inc

N/A

Current Price

$1.28

Market Cap

23.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUR
RDI
Founded
2001
1937
Country
Israel
United States
Employees
N/A
2005
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
25.5M
23.4M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
PLUR
RDI
Price
$2.09
$1.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
10.1K
19.2K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
10.78
N/A
EPS
N/A
N/A
Revenue
$1,336,000.00
N/A
Revenue This Year
$97.38
$16.25
Revenue Next Year
$293.97
$4.04
P/E Ratio
N/A
N/A
Revenue Growth
309.82
N/A
52 Week Low
$1.99
$0.94
52 Week High
$5.96
$1.65

Technical Indicators

Market Signals
Indicator
PLUR
RDI
Relative Strength Index (RSI) 37.48 56.24
Support Level N/A $0.99
Resistance Level $2.58 $1.29
Average True Range (ATR) 0.12 0.08
MACD 0.02 0.00
Stochastic Oscillator 22.73 55.56

Price Performance

Historical Comparison
PLUR
RDI

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: